Generation of Induced Pluripotent Stem Cells from Muscular Dystrophy Patients: Efficient Integration-free Reprogramming of Urine Derived Cells
January 28th, 2015
10.5K views
This protocol entails detailed procedures for isolation of urine derived cells from muscular dystrophy patients; their efficient and rapid reprogramming through Sendai virus transduction.
Overview
This protocol describes the isolation of urine-derived cells from muscular dystrophy patients and their rapid reprogramming using Sendai virus transduction. The method allows for the generation of induced pluripotent stem cells (iPSCs) in a non-invasive manner.
Key Study Components
Area of Science
- Cell Biology
- Stem Cell Research
- Muscular Dystrophy
Background
- Induced pluripotent stem cells (iPSCs) can be generated from various somatic cells.
- Traditional methods often involve invasive procedures.
- Urine-derived cells provide a non-invasive alternative.
- Sendai virus is used for efficient reprogramming without integration.
Purpose of Study
- To develop a protocol for generating iPSCs from muscular dystrophy patients.
- To utilize urine-derived cells for a non-invasive approach.
- To confirm the transgene-free state of iPSCs.
Methods Used
- Collection of urine samples from muscular dystrophy patients.
- Isolation and expansion of urine-derived cell cultures.
- Transduction of cells with Sendai virus containing Yamanaka factors.
- Confirmation of pluripotent stem cells by R-T-P-C-R analysis.
Main Results
- Typical pluripotent-like colonies emerged after 12 days of transduction.
- Transgene-free state confirmed by passage 13.
- The method is efficient compared to traditional reprogramming techniques.
- Non-invasive collection of cells is a significant advantage.
Conclusions
- This protocol provides a reliable method for generating iPSCs from patients.
- It highlights the potential of urine-derived cells in regenerative medicine.
- The use of Sendai virus allows for a zero footprint reprogramming approach.
Frequently Asked Questions
What are induced pluripotent stem cells (iPSCs)?
iPSCs are cells that have been genetically reprogrammed to an embryonic stem cell-like state, allowing them to differentiate into various cell types.
Why use urine-derived cells for reprogramming?
Urine-derived cells can be collected non-invasively, making them a convenient source for generating iPSCs.
What is the role of Sendai virus in this protocol?
Sendai virus is used to deliver Yamanaka factors for reprogramming cells without integrating into the host genome.
How is the transgene-free state confirmed?
The transgene-free state is confirmed through R-T-P-C-R analysis at passage 13 of the iPSCs.
What are the advantages of this method over traditional techniques?
This method is less invasive, faster, and avoids the risks associated with integrating viral vectors.
Can this method be applied to other diseases?
Yes, the protocol can potentially be adapted for other conditions where non-invasive cell sourcing is beneficial.
Executive Industry Relevance
Generating patient-specific iPSCs from muscular dystrophy patients using non-invasive urine-derived cells enables scalable, safety-compliant disease modeling for target validation and preclinical screening. This integration-free reprogramming approach reduces biological risk in early discovery by providing transgene-free, genetically matched human cellular systems. The method supports mechanistic de-risking and predictive confidence in therapeutic hypothesis testing for cardiomyopathy and skeletal muscle pathologies.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of dystrophin-deficient phenotypes in human iPSC-derived cardiomyocytes to validate disease-relevant targets.
- Operational Value: Provides renewable, patient-matched cellular sources for functional target screening without invasive biopsies.
- Predictive Value: Supports phenotypic screening of compounds in disease-relevant human cellular models to improve lead identification confidence.
Screening & Assay Development
- Scientific Value: Generates standardized, transgene-free iPSC lines suitable for assay development in cardiac and skeletal muscle dysfunction.
- Operational Value: Enables scalable expansion of clonal iPSCs for reproducible, high-content screening workflows.
- Assay Readiness: Supports quantitative readouts such as contractility, calcium handling, and biomarker expression in differentiated progeny.
Translational & Preclinical Research
- Scientific Value: Facilitates continuity from discovery to preclinical validation by modeling dystrophic cardiomyopathy in vitro.
- Operational Value: Provides genetically defined systems for evaluating target engagement and pathway modulation.
- Predictive Confidence: Enables risk-adjusted advancement decisions through mechanistic de-risking of therapeutic candidates.
Pipeline & Workflow Integration
The method fits within the discovery continuum from early target hypothesis testing through lead identification to preclinical efficacy assessment, leveraging non-invasive cell sourcing and integration-free reprogramming.
- Discovery Biology: Supports hypothesis testing and pathway clarification in muscular dystrophy using patient-derived iPSCs.
- Screening: Enables assay standardization and quantitative measurement of phenotypic rescue in differentiated cardiomyocytes.
- Analytics: Provides transgene-free, genetically matched cellular systems for reliable comparison of treatment conditions.
- Translational Research: Connects iPSC-derived cardiomyocytes to preclinical validation of disease mechanisms and therapeutic response.
- Enterprise Reuse: Establishes a scalable, non-invasive platform for generating disease-specific iPSCs across multiple muscular dystrophy models.
Operational & Enterprise Impact
- Scientific Value: Predictive confidence in target validation through human-relevant, genetically accurate disease models.
- Operational Value: Standardization and reproducibility via clonal, transgene-free iPSC lines from non-invasive sources.
- Strategic Value: Improved go/no-go decisions by reducing late-stage biological risk through early mechanistic de-risking.
- Portfolio Impact: Risk-adjusted prioritization of therapeutics based on efficacy in patient-derived cellular systems.
Implementation Considerations
- Expertise in stem cell culture, reprogramming, and differentiation protocols.
- Access to BSL-2 facilities, centrifuges, and fluorescence or PCR-based validation tools.
- Standardization of urine cell isolation and expansion across donor samples.
- Adaptation to different muscular dystrophy genotypes and differentiation lineages.
- Limitations include variability in urine cell yield and reprogramming efficiency across patient samples.
Biopharma FAQs
Why does transgene-free confirmation matter for target validation?
Confirming the transgene-free state by passage 13 ensures that observed phenotypes in iPSC-derived cardiomyocytes are not confounded by residual vector expression, supporting reliable target validation and mechanistic de-risking in discovery.
How does non-invasive urine cell collection fit the discovery pipeline?
Non-invasive collection of urine-derived cells enables scalable, patient-sourced iPSC generation without biopsies, supporting early discovery workflows and longitudinal sampling for target validation studies.
What quantitative measurements enable assessment of reprogramming efficiency?
Quantitative assessment includes monitoring clonal emergence by day 12, TRA-1-81+ live cell staining for pluripotency, and R-T-P-C-R analysis to confirm transgene silencing by passage 13, enabling standardized screening readiness.
Why do replication requirements matter for cross-functional collaboration?
Replication of transgene-free iPSC clones ensures consistency across discovery, screening, and preclinical teams, supporting reliable data transfer and reducing variability in target validation and assay development.
What statistical analysis capabilities are required before implementation?
Implementation requires statistical comparison of pluripotency marker expression, differentiation efficiency, and transgene silencing rates across clones and passages to ensure reproducibility and confidence in phenotypic screening outputs.
Chapters in this video
0:05
Title
1:46
Isolation and Expansion of Urine Cells
4:06
Urine Cell Reprogramming Using Sendai Virus
5:30
Urine Derived Induced Pluripotent Stem Cell (iPSC) Clonal Expansion
6:53
Results: Representative Generation of Viral Genome and Transgene Free iPSCs
8:36
Conclusion
